Effects of Ferulic Acid and <i>Angelica archangelica</i> Extract (Feru-guard ^® ) on Mild Cognitive Impairment: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Prospective Trial

Abstract

We conducted a multicenter, randomized, double-blind, placebo-controlled prospective trial examining a supplement containing ferulic acid and Angelica archangelica extract (Feru-guard ® ) for mild cognitive impairment (MCI). In the intention-to-treat population, Mini-Mental State Examination (MMSE) scores were significantly better at 24 weeks ( p = 0.041) in the active group. In the per protocol population, MMSE was significantly better in the active group at 24 weeks ( p = 0.008), and mixed effect models for repeated measures (MMRM) showed significant difference ( p = 0.016). ADAS-Jcog was significantly better at 24 ( p = 0.035) and 48 weeks ( p = 0.015) in the active group, and MMRM was significant ( p = 0.031). Thus, Feru-guard ® may be useful for MCI.